Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Acumen Pharmaceuticals, Inc. (ABOS)

Acumen reports Q3 2026 net loss of $25.4 million; cash falls to $78.6 million

Mixed Impact 3 of 5 earnings Written later

Acumen Pharmaceuticals reported a third-quarter 2026 net loss of $25.4 million, narrower than $26.5 million a year earlier, and cash, cash equivalents and marketable securities of $78.6 million at September 30, 2026, down from $110.2 million at June 30, 2026. The company expects the cash to fund current clinical and operational activities into early 2027 and said topline results from its Phase 2 ALTITUDE-AD study are expected in November 2026.

Key points

  • Net loss was $25.4 million for the quarter ended September 30, 2026, versus $26.5 million a year earlier; loss per share was $0.35 versus $0.44.
  • Cash, cash equivalents and marketable securities were $78.6 million at September 30, 2026, versus $110.2 million at June 30, 2026, with runway expected into early 2027.
  • R&D expenses were $21.1 million versus $22.0 million a year earlier, mainly due to lower manufacturing, materials and CRO costs tied to ALTITUDE-AD.
  • Topline ALTITUDE-AD Phase 2 results for sabirnetug are expected in November 2026.

The filing

CompanyAcumen Pharmaceuticals, Inc. (ABOS)
Form8-K, current report
Filed with the SECOct 26, 2026, 7:09 AM ET
Accession number0001628280-26-067129

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.